DexCom (DXCM) is a publicly traded Continuous Glucose & Metabolic company founded in 1999 and based in San Diego, United States.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Apr 14, 2005 | IPO | $56.4M | — | Piper Jaffray |
| Jun 5, 2002 | Series C | $30M | — | RWI Group and Affiliates |
DexCom reported Q3 2026 revenue of $1.344 billion, up 11% year-over-year on both a reported and organic basis. U.S. revenue grew 14% and international revenue grew 5%. GAAP operating income was $327.2 million, or 24.3% of revenue, up from $242.5 million (20.1%) in Q3 2025. GAAP net income was $275.1 million, or $0.72 per diluted share, compared with $283.8 million, or $0.70 per diluted share, a year earlier. Adjusted (non-GAAP) operating income was $339.5 million, or 25.3% of reported revenue. Operationally, the company reported that CONNECT, a randomized trial of Dexcom G7 in Type 2 diabetes not on insulin, was published in the New England Journal of Medicine after quarter end; it also relaunched Stelo, rolled out the G7 15 Day System in the U.S., and received its first two international regulatory clearances for that system. For fiscal 2026, the company raised its revenue guidance to $5.20–$5.25 billion (about 12–13% growth) and raised its non-GAAP operating margin guidance to approximately 24%, while reiterating non-GAAP gross profit margin of approximately 64%. It also announced a share repurchase authorization of up to $1.0 billion. Cash and marketable securities totaled $1.82 billion at September 30, 2026.
FY2026 revenue $5.20–$5.25B (about 12–13% growth); non-GAAP operating margin ~24%; non-GAAP gross profit margin ~64%

DexCom will launch its 15-day G7 CGM system in Canada in November.

DexCom unveils a new sensor model and expands Medicare coverage, per a truncated Pluang headline.

Seeking Alpha analysis argues DexCom's improving patient access supports a long-term buy rating.

DexCom brings its 15-day glucose monitor to Canada.

DexCom's Q3 earnings beat forecasts, with the company looking ahead to type 2 diabetes coverage.

DexCom's Q3 analysis points to clinical momentum and new product launches supporting its growth trajectory.
Dexcom G7 is the company's latest continuous glucose monitoring (CGM) system, featuring a fully integrated all-in-one sensor and transmitter worn on the upper arm. It delivers real-time glucose readings directly to a smartphone with a 30-minute warm-up — the shortest of any CGM on the market. The G7 supports 10-day wear (with a 15-day version available), is compatible with automated insulin delivery (AID) systems like Omnipod 5 and Tandem t:slim X2, and enables direct-to-Apple-Watch connectivity so users can view glucose data without carrying their phone. Its smaller, streamlined design and improved accuracy at the low end make it a top choice for people with Type 1 and Type 2 diabetes managing intensive insulin therapy.
Dexcom G6 is the previous-generation CGM system that set the standard for fingerstick-free diabetes management. It uses a two-piece design — a disposable sensor worn for 10 days and a reusable transmitter that lasts up to three months — to stream real-time glucose data to a smartphone or compatible receiver. The G6 requires no routine fingerstick calibration and offers customizable alerts for high and low glucose levels. It leads the industry in pump connectivity, integrating with multiple automated insulin delivery systems including Tandem, Omnipod, and Insulet devices, making it a reliable choice for users who need robust interoperability.
Stelo is Dexcom's over-the-counter (OTC) CGM launched in 2024, available without a prescription for adults with Type 2 diabetes who do not use insulin. It provides continuous glucose readings and insights directly to a smartphone app, helping users understand how food, activity, and daily routines affect their blood sugar. Stelo is designed for the broader wellness and prediabetes market — people who want to track their glucose patterns to make informed lifestyle adjustments. It uses the same sensor technology as Dexcom's prescription CGMs but is tailored with a simplified app experience focused on education and trend awareness rather than clinical alerts.